Highbridge Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Highbridge Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,482,836	Closed	-$15.2M	–	546
2022 Q4	$15.2M	Sell	1,482,836 -588,215	-28%	-$5.97M	0.42%	85
2022 Q3	$20.8M	Buy	2,071,051 +658,944	+47%	+$6.59M	0.29%	50
2022 Q2	$14.2M	Buy	1,412,107 +225,958	+19%	+$2.24M	0.32%	94
2022 Q1	$11.7M	Buy	+1,186,149	New	+$11.7M	0.27%	108

Other funds holding BIOS

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.46% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Highbridge Capital Management's BIOS Position: Q1 2023 in Review

Highbridge Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q1 2023, closing a stake of 1,482,836 shares — an estimated $15.2M sold.

Highbridge Capital Management first reported a position in BIOS in Q1 2022 and held it in 4 quarters. The position peaked at $20.8M in Q3 2022. 61 funds tracked by Wall St. Rank hold BIOS as of Q1 2023.

Highbridge Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Highbridge Capital Management sold 1,482,836 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $15.2M.
Highbridge Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
Highbridge Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $20.8M in Q3 2022.
61 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Highbridge Capital Management's 13F filing for Q1 2023, filed 11 May 2023.